Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin

Overview

This is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome (ACS) patients by measuring serum neopterin levels. Serum neopterin is a marker for measuring macrophage activation. Prior studies have illustrated that there are elevated serum neopterin levels in ACS. Patients enrolled are those with ACS. Blood samples are drawn at presentation, and at 72 hours after admission, or at office visits and at 72 hours later. Neopterin levels are measured via a commercially available assay..

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2011

Detailed Description

The study is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome (ACS) patients by measuring serum neopterin levels. Serum neopterin is a marker for measuring macrophage activation. Prior studies have illustrated that there are elevated serum neopterin levels in ACS. The investigators' study focused on comparing different treatment arms with regard to their neopterin levels and correlating neopterin levels to the Thrombolysis in Myocardial Infarction (TIMI) risk score. Patients enrolled are those with ACS. Blood samples are drawn at presentation, and at 72 hours after admission, or at office visits and at 72 hours later. Neopterin levels are measured via a commercially available assay.

Arms, Groups and Cohorts

  • Patients diagnosed with acute coronary syndrome (ACS)

Clinical Trial Outcome Measures

Primary Measures

  • Determine if serum neopterin is a useful marker in risk stratifying patients with acute coronary syndromes as it relates to vascular endothelial dysfunction.
    • Time Frame: 8 year study – 2011 anticipated study completion

Secondary Measures

  • Evaluate whether serum neopterin is a useful marker in a similar manner as LPGD-S.
    • Time Frame: 5 years

Participating in This Clinical Trial

Inclusion Criteria

  • Chest pain and either ST segment elevation or depression > 0.1 mV in at least 2 contiguous electrocardiographic leads as well as elevation in troponin levels. Exclusion Criteria:

  • History of medical conditions known to alter neopterin concentrations in blood. The exclusion criteria includes: – renal failure, – history of HIV, – transplant patients, – active infections, – history of autoimmune disease, – malignancy, – phenylketonuria, – immune mediated liver disease, and – patients taking immunomodulating therapy.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Winthrop University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Barbara George, Research Coordinator – Winthrop University Hospital
  • Overall Official(s)
    • Joshua DeLeon, MD, Principal Investigator, Winthrop University Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.